Quantcast

Latest Antibody Stories

2014-07-10 12:30:51

ST. PETERSBURG, Russia, July 10, 2014 /PRNewswire/ -- On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD [http://biocad.ru/en ]. The Company is developing a unique project called MabNext [http://biocad.ru/en/science ]. Within the scope of MabNext project BIOCAD develops a number of innovative drugs based on monoclonal antibodies for treatment of cancer and autoimmune...

2014-07-08 04:21:35

OXFORD, England and SAN JOSE, California, July 8, 2014 /PRNewswire/ -- Oxford BioTherapeutics, an international biotechnology company focused on the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced today the appointment of Eugen Leo, MD, PhD, MBA, as Head of Clinical Development. Dr. Leo brings substantial clinical development experience of targeted and first-in-class molecules, as well as extensive translational research...

First Antibodies To Treat Cancer In Dogs Developed
2014-07-07 03:10:21

University of Veterinary Medicine Vienna Nearly every second dog develops cancer from the age of ten years onward. A few therapies derived from human medicine are available for dogs. A very successful form of therapy by which antibodies inhibit tumor growth has not been available for animals so far. Scientists at the inter-university Messerli Research Institute of the Vetmeduni Vienna, the Medical University of Vienna, and the University of Vienna have developed, for the first time,...

2014-07-03 08:23:49

MUMBAI,India, July 3, 2014 /PRNewswire/ -- - GBR 830 is an antagonistic monoclonal antibody with first in class potential for the treatment of autoimmune diseases targeting OX40, a co-stimulatory receptor on T cells - The antibody has successfully completed the Phase I enabling preclinical development program and a Phase I clinical trial application has been filed with The Netherlands authorities -...

2014-07-01 12:28:27

COLLEGE PARK, Md., July 1, 2014 /PRNewswire-USNewswire/ --The University of Maryland (UMD) Fischell Department of Bioengineering and the Maryland Center for Excellence in Regulatory Science (M-CERSI) have partnered with the Global Biological Standards Institute (GBSI) to launch the Collaboration to Advance Antibody Standards. This collaboration between the Fischell Department of Bioengineering and GBSI will allow for assessment of the current antibody standards landscape and...

2014-06-30 23:08:23

New research study “Antibody Partnering Terms and Agreements” worked out by CurrentPartnering is now available at MarketPublishers.com. London, UK (PRWEB) June 30, 2014 What are the major big pharma companies involved in the antibody market space? What are the prevailing trends in antibody dealmaking in the overall biopharma industry since 2007? What does the company’s recent antibody dealmaking activity look like? What is actually granted by the antibody dealmaking agreement to a...

2014-06-28 09:28:48

University of Texas Medical Branch at Galveston Human antibody therapy successfully combats virus 5 days after infection An interdisciplinary research team from the University of Texas Medical Branch at Galveston, the Uniformed Services University of the Health Sciences and three groups within the National Institutes of Health reports a new breakthrough in countering the deadly Nipah virus. The human monoclonal antibody known as m102.4 is the first effective antiviral treatment for...

2014-06-27 23:09:30

Slide represents new diagnostic tool for detection of PEDV antibody. Pullman, WA (PRWEB) June 27, 2014 VMRD announced today the availability of a substrate slide that can be used for the detection of antibody to porcine epidemic diarrhea virus (PEDV). The slides are of twelve-well, Teflon-masked format with a substrate of fixed (killed), PEDV-infected Vero cells interspersed with non-infected Vero cells. “This substrate slide is the first quality-controlled FA diagnostic tool for...

2014-06-18 23:16:14

Bacterial recombinant protein expression is now available as a service at Maine Biotechnology Services. When MBS develops recombinant antigen for a hybridoma development, the end use application of the antibodies is considered during every phase of antigen production. Portland, Maine (PRWEB) June 18, 2014 Maine Biotechnology Services is announcing the addition of Bacterial Recombinant Protein Expression and Purification services to compliment our complete antibody service offering, adding...

2014-06-11 08:29:19

LA JOLLA, Calif. and SHANGHAI, June 11, 2014 /PRNewswire/ -- RuiYi, Inc., a global therapeutic innovation leader, announced today the close of a $4 million debt financing from Silicon Valley Bank to advance a pipeline of novel monoclonal antibodies (mAb) targeting G protein coupled receptors (GPCRs). RuiYi plans to file an IND and initiate clinical trials in multiple countries in 2015 for the company's lead asset, RYI-008, a novel anti-IL-6 mAb for rheumatoid arthritis and cancer....


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related